Acute Myeloid Leukaemia

Description

How might the treatment paradigm change for AML? Why do KOLs say Roche/AbbVie's Venclexta/Venclyxto and azacitidine will remain the standard of care for newly diagnosed AML patients ineligible for intensive chemotherapy? Why do experts believe Novartis' Rydapt could come under pressure from Astellas Pharma's Xospata? KOLs are eagerly anticipating trial results for Syndax Pharmaceuticals' revumenib - why? KOLs critically assess the prospects of launched and pipeline therapies.

Key questions answered:

What factors do US KOLs say are limiting uptake of Daiichi Sankyo's FLT3 inhibitor Vanflyta?
Why do experts see a limited role for AROG Pharmaceuticals/Pfizer's FLT3 inhibitor crenolanib?
Why would most KOLs use Rigel Pharmaceuticals/Forma Therapeutics' Rezlidhia over Servier's Tibsovo in R/R IDH1 mutated AML?
What Phase III trial data do KOLs say could see Jazz Pharmaceuticals' Vyxeos become the standard chemotherapy backbone?
What practical challenges do experts identify for Actinium Pharmaceuticals' Iomab-B and Actimab-A pipeline therapies?
What underpins KOLs' opinions that menin inhibitors could have a practice-changing impact?

Key brands covered in this report:

Venclexta/Venclyxto (venetoclax)
Rydapt (midostaurin)
Xospata (gilteritinib)
Vanflyta (quizartinib)
crenolanib
Tibsovo (ivosidenib)
Idhifa (enasidenib)
Rezlidhia (olutasidenib)
Vyxeos (daunorubicin + cytarabine liposome for injection)
Onureg (oral azacitidine)

Inqovi/Inaqovi (ASTX727)
Daurismo (glasdegib)
Mylotarg (gemtuzumab ozogamicin)
Iomab-B (131I apamistamab)
Actimab-A (lintuzumab-Ac225)
uproleselan
galinpepimut-S
revumenib
ziftomenib

Executive summary (10)

Treatment algorithm for acute myeloid leukaemia

Research objectives (10)

BCL-2 inhibitors (18)

Approved drugs (18)
- Venclexta/Venclyxto (venetoclax; AbbVie/Roche) (18)

FLT3 inhibitors (23)

Approved drugs (17)
- Rydapt (midostaurin; Novartis), Xospata (gilteritinib; Astellas Pharma) and Vanflyta (quizartinib; Daiichi Sankyo) (17)
Pipeline drugs (6)
- Crenolanib (AROG Pharmaceuticals/Pfizer) (6)

IDH1/2 Inhibitors (19)

Approved drugs (19)
- Tibsovo (ivosidenib; Servier), Idhifa (enasidenib; Servier/Bristol Myers Squibb) and Rezlidhia (olutasidenib; Rigel Pharmaceuticals/Forma Therapeutics) (19)

Novel formulation chemotherapies and hypomethylating agents (24)

Approved drugs (24)
- Vyxeos (daunorubicin + cytarabine liposome for injection; Jazz Pharmaceuticals) (11)
- Onureg (CC-486/oral azacitidine; Bristol Myers Squibb) (5)
- Inqovi/Inaqovi (ASTX727; Astex Pharmaceuticals/Otsuka Pharmaceuticals) (8)

Hedgehog inhibitors (4)

Approved drugs (4)
- Daurismo (glasdegib; Pfizer) (4)

Antibody-drug conjugates and radioimmunoconjugates (15)

Approved drugs (4)
- Mylotarg (gemtuzumab ozogamicin; Pfizer) (4)
Pipeline drugs (11)
- Iomab-B (131I apamistamab; Actinium Pharmaceuticals) (6)
- Actimab-A (lintuzumab-Ac225; Actinium Pharmaceuticals) (5)

Other mechanisms of action (21)

Pipeline drugs (21)
- Uproleselan (GlycoMimetics) (6)
- Galinpepimut-S (SELLAS Life Sciences) (6)
- Revumenib (Syndax Pharmaceuticals) and ziftomenib (Kura Oncology) (9)

Future trends and opportunities in AML treatment (4)

Appendix (4)

KOL details (4)
- KOLs from the US (2)
- KOLs from Europe (1)

Acute Myeloid Leukaemia - KOL Insight